Ionis Pharmaceuticals IONS Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's short-term investments?
- Ionis Pharmaceuticals (IONS) reported short-term investments of $1.12B in Q1 2026.
- How has Ionis Pharmaceuticals's short-term investments changed year-over-year?
- Ionis Pharmaceuticals's short-term investments decreased by 9.4% year-over-year, from $1.23B to $1.12B.
- What is the long-term trend for Ionis Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's short-term investments has grown at a 1.1% compound annual growth rate (CAGR), from $1.49B to $1.58B.
- What does short-term investments mean?
- Highly liquid investments that can be converted to cash within one year.
- How do you interpret short-term investments?
- Higher levels indicate strong liquidity and a robust ability to fund near-term R&D or operational costs.
- How does short-term investments compare across companies?
- Biotech companies typically maintain significant short-term investments to ensure continuous funding for clinical trials.